AbbVie (ABBV) Stock Moves -1.64%: What You Should Know

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day. At the same time, the Dow lost 2.48%, and the tech-heavy Nasdaq lost 2.55%.The drugmaker's stock has dropped by 17.63% in the past month, falling short of the Medical sector's loss of 9.83% and the S&P 500's loss of 5.6%.Market participants will be closely following the financial results of AbbVie in its upcoming release. The company plans to announce its earnings on April 25, 2025. In that report, analysts expect AbbVie to post earnings of $2.47 per share. This would mark year-over-year growth of 6.93%. Alongside, our most recent consensus estimate is anticipating revenue of $12.88 billion, indicating a 4.65% upward movement from the same quarter last year.ABBV's full-year Zacks Consensus Estimates are calling for earnings of $12.27 per share and revenue of $59.55 billion. These results would represent year-over-year changes of +21.25% and +5.72%, respectively.Investors might also notice recent changes to analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.3% downward. AbbVie presently features a Zacks Rank of #3 (Hold).In the context of valuation, AbbVie is at present trading with a Forward P/E ratio of 14.09. This valuation marks a premium compared to its industry's average Forward P/E of 13.38.We can also see that ABBV currently has a PEG ratio of 1.18. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.18 as of yesterday's close.The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 27% of all 250+ industries.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks